目的 探讨华蟾素注射液对与人肝癌HepG-2细胞共培养下人淋巴内皮细胞增殖、迁移及管状结构形成的影响。方法 采用Transwell方法建立HepG-2细胞与人淋巴内皮细胞共培养系统;通过绘制细胞生长曲线,观察华蟾素注射液对共培养系统中人淋巴内皮细胞增殖的影响;通过细胞迁移实验,观察华蟾素注射液对共培养系统中人淋巴内皮细胞迁移的影响;通过基质胶实验,观察华蟾素注射液对共培养系统中人淋巴内皮细胞管状结构形成的影响。结果 华蟾素注射液能够显著抑制与HepG-2细胞共培养下人淋巴内皮细胞增殖(P<0.05),迁移(P<0.05)及管状结构形成(P<0.05),呈剂量依赖性。结论 华蟾素注射液抑制与HepG-2细胞共培养下人淋巴内皮细胞增殖,迁移及管状结构形成,可能是华蟾素注射液抑制肿瘤淋巴道转移的机制之一。
Abstract
To study the effect of cinobufacini injection on proliferation,migration and tube-like structure formation of human hepatoma HepG-2 cells co-cultured with human lymphatic endothelial cells. METHODS Co-culture system of human hepatoma HepG-2 cells and human lymphatic endothelial cells is established by means of transwell chamber; cell growth curve is used to observe the effect of cinobufacini injection on the proliferation of HLEC co-cultured with HepG-2 cells;migration assay is used to observe the effect of cinobufacini injection on the migration of HLEC co-cultured with HepG-2; matrigel assay is used to observe the effect of cinobufacini injection on the tube-like structure formation of HLEC co-cultured with HepG-2 cells. RESULTS Cinobufacini injection significantly inhibits proliferation(P<0.05),migration(P<0.05)and tube-like structure formation(P<0.05)of HLEC co-cultured with HepG-2 cells in dose dependent ways.CONCLUSION Cinobufacini injection inhibits proliferation,migration and tube-like structure formation of HLEC co-cultured with HepG-2 cells,which might contribute the inhibiting mechanisms of cinobufacini injection on tumor metastasis.
关键词
华蟾素注射液 /
HepG-2细胞 /
人淋巴内皮细胞 /
增殖 /
迁移:管状结构形成
{{custom_keyword}} /
Key words
cinobufacini injection /
HepG-2 cell /
HLEC /
proliferation /
migration /
tube-like structure formation
{{custom_keyword}} /
中图分类号：
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]ZHOU L M, GUO J M. Research progress in targeted therapy for hepatocellular carcinoma. J Oncol(肿瘤学杂志), 2009,15(2):156-161.[2] CHENG A L, KANG Y K, CHEN Z, et al.Efficacy and safety of sorafenib in patientsin the Asia-Pacific region with advancedhepatocellular carcinoma:Aphase Ⅲ randomised, double-blind,placebocontrolled trial . Lancet Oncol,2009, 10(1):25-34.[3] CHEN H,SUN Y,CUI X N.The effect of cinobufacini injection on DNA topoisomerase Ⅰ of human hepatocellular carcinoma HepG-2 cells.China Oncol (中国癌症杂志), 2010, 20(3):197-201.[4] SUN Y,SHAN L J,LIU Y J,et al.Impact of cinobufacini injection on proliferation and cell cycle of human hepatoma HepG-2 cells.China Cancer(中国肿瘤),2010,19(6):41-43.[5] ZHI Q M,PEI Y Y,YE H S,et al.Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer,2009,115(22):5309-5318. [6] ZUO X D, CUI Y A. Cinobufotalin antitumor clinical research[J].Chin Clin Oncol(临床肿瘤学杂志), 2003,8(3):232-235.[7] ZHAGN D,LI B,SHI J, et al.Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein. Cancer Res, 2010, 70(6):2495-2503.[8] TAN Y Z,WANG H J.Effects of extracellular matrix on lymphanglogenesis in vitro.Acta Anatom Sin(解剖学报),2002,33(1):69-72.[9] ICHIKAWA M, WILLIAMS R, WANG L,et al.S100A8/A9 activate key genes and signaling pathways in colon tumor progression.Mol Cancer Res, 2011,9(2):133-148.[10] ZHU X Y, LIU L M. Research progress on the antitumor mechanism of cinobutacini injection and its active ingredient[J]. Tumour J World, 2006, 5(4):272-275.[11] NAKAZAWA K,KALASSY M,SAHUC F,et al.Pigmented human skin equivalent-as a model of the mechanisms of control of cell-cell and cell-matrix interactions.1998,36(6):813-820.[12] LINCOLN LI D W,PHILLIPS P G,BOVE K.Estrogen-induced Ets-1 promotes capillary formation in an in vitro tumor angiogenesis model.Breast Cancer Res Treat,2003,78(2):167-178.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(845 KB)
